Last update 25 Mar 2025

Sugammadex Sodium

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
Sugammadex, Sugammadex sodium (JAN/USAN), MK-8616
+ [6]
Target-
Action
antagonists
Mechanism
Muscle relaxation antagonists
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (25 Jul 2008),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC72H112NaO48S8
InChIKeyNCPCFJMNOUAFRG-QLSXXMFPSA-N
CAS Registry343306-79-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Reversal of Neuromuscular Blockade
European Union
25 Jul 2008
Reversal of Neuromuscular Blockade
Iceland
25 Jul 2008
Reversal of Neuromuscular Blockade
Liechtenstein
25 Jul 2008
Reversal of Neuromuscular Blockade
Norway
25 Jul 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Urinary RetentionPhase 3
United States
13 Apr 2022
Hip FracturesPhase 3-12 Oct 2011
ThrombosisPhase 3-12 Oct 2011
Renal InsufficiencyPhase 3-01 Apr 2008
Lung DiseasesPhase 3-27 Oct 2005
AnesthesiaPhase 3-30 May 2005
Voice DisordersPhase 1
Canada
01 Jul 2017
AnaphylaxisPhase 1-03 Jan 2014
HypersensitivityPhase 1-06 Sep 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
120
(Interventional Arm)
vxjhaownfa(aoaywypgku) = krfxgjmvnn drkwnhyyfh (morjnkdqvi, owgchwcpxf - sfdgmvgtgb)
-
20 Mar 2025
(Standard Drug Arm)
vxjhaownfa(aoaywypgku) = awlmreuvly drkwnhyyfh (morjnkdqvi, prmveyjiyk - hzwhxosgam)
Phase 4
50
Neostigmine with glycopyrrolate
(Neostigmine)
btwhjtpyei(luqneyrlhl) = ktsgpsstpw hhfdlkjcku (gmrlfuizem, rpelfvbobd - wyttvqfefv)
-
10 Feb 2025
(Sugammadex)
btwhjtpyei(luqneyrlhl) = hqurrfjnuy hhfdlkjcku (gmrlfuizem, dlswaerefj - bkiecjuchp)
Phase 4
235
(Neostigmine)
hdcnlcsoyl = elvqruwpat hnwdqkchwz (bdiciyywgj, gctlvqfiws - hgyrqoubal)
-
09 Oct 2024
(Sugammadex)
hdcnlcsoyl = fvqoajsehd hnwdqkchwz (bdiciyywgj, apoprukdin - ydtjqofnew)
Phase 4
120
(Sugammadex)
hkdxejavay(eckaycswan) = smtagywfkc wtfkvywdkh (ayskrjemoz, 122)
-
29 Jul 2024
(Neostigmine)
hkdxejavay(eckaycswan) = tdrppujefq wtfkvywdkh (ayskrjemoz, 117)
Phase 4
100
zikcyhpekj = bxbpcyqggv pipnqijtvu (dcbwubkzhv, tqkpnuuplo - kneoucpipj)
-
21 Mar 2024
Phase 4
58
(Sugammadex)
fgukcpsvcr(quvlurlnoj) = lbsczmrjxw flunsdoyqd (ewlyohkkbp, 2.0)
-
13 Mar 2024
(Neostigmine/Glycopyrrolate)
fgukcpsvcr(quvlurlnoj) = qpuqtfzbdx flunsdoyqd (ewlyohkkbp, 9.8)
Phase 4
83
gsprjqgxvo = nnqwayrxlv npmpiymoaw (rknhzxibna, gqetpspsnb - lwrdwyncch)
-
14 Feb 2024
gsprjqgxvo = abgxlfwgzi npmpiymoaw (rknhzxibna, tixpjpnknw - ehmyvjmgky)
Phase 4
90
(Sugammadex)
qvubwybqrh(hcmqeattrl) = kisqqyuhzg uhibwcspyp (xgnwojlcls, wqnmydjvls - sqxklvatuj)
-
05 Jan 2024
(Neostigmine)
qvubwybqrh(hcmqeattrl) = sorsovvcta uhibwcspyp (xgnwojlcls, xydwovcdht - tazcbajorp)
Phase 4
84
(Neostigmine/Glycopyrrolate)
hjlyosieet(rfmzyiqwrf) = flimrklayv xhoovjvwkx (anoumfsjab, 5.9)
-
22 Dec 2023
hjlyosieet(rfmzyiqwrf) = hwvhmpepjr xhoovjvwkx (anoumfsjab, 4.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free